Literature DB >> 11518767

12(S)-Hydroperoxy-eicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets.

C Calzada1, E Véricel, B Mitel, L Coulon, M Lagarde.   

Abstract

Lipid hydroperoxides have been reported to regulate cell function and eicosanoid formation. The aim of the present study was to determine the effect of 12(S)-hydroperoxy-eicosatetraenoic acid [12(S)-HPETE], the platelet 12-lipoxygenase-derived hydroperoxide of arachidonic acid (AA), on the availability of nonesterified AA, which represents a rate-limiting step in the biosynthesis of eicosanoids. The coincubation of human platelets with concentrations of 12(S)-HPETE below 50 nM and subthreshold concentrations (STC) of collagen (less than 0.24 microg/ml) significantly enhanced platelet aggregation and the formation of thromboxane B(2), the stable catabolite of the potent aggregating agent thromboxane A(2). In addition, the nonesterified endogenous AA concentration increased by 3-fold. Arachidonoyl-containing molecular species concentrations of 1,2-diacyl-glycero-3-phosphocholine, 1-alkyl-2-acyl-glycero-3-phosphocholine, and 1-alkenyl-2-acyl-glycero-3-phosphoethanolamine decreased specifically in response to 12(S)-HPETE, whereas no significant changes were observed within 1,2-diacyl-glycero-3-phosphoethanolamine and 1,2-diacyl-glycero-3-phosphoinositol molecular species. The 12(S)-HPETE-induced increase in nonesterified AA was fully prevented by arachidonoyl trifluoromethyl ketone, an inhibitor of cytosolic phospholipase A(2) (cPLA(2)), and cPLA(2) was translocated to membranes and phosphorylated in platelets incubated with 12(S)-HPETE. In conclusion, these results indicate that nanomolar concentrations of 12(S)-HPETE could play a significant role in controlling the level of endogenous AA and the formation of thromboxane, thereby potentiating platelet function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518767

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  12-lipoxygenase: a potential target for novel anti-platelet therapeutics.

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2011-07-01

2.  RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency.

Authors:  Gurpreet Kaur; Gauthami Jalagadugula; Guangfen Mao; A Koneti Rao
Journal:  Blood       Date:  2010-02-24       Impact factor: 22.113

3.  LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets.

Authors:  R Colas; A Sassolas; M Guichardant; C Cugnet-Anceau; M Moret; P Moulin; M Lagarde; C Calzada
Journal:  Diabetologia       Date:  2011-08-17       Impact factor: 10.122

Review 4.  Pathophysiologic role of redox status in blood platelet activation. Influence of docosahexaenoic acid.

Authors:  M Lagarde; C Calzada; E Véricel
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

5.  Cytosolic phospholipase A2: targeting cancer through the tumor vasculature.

Authors:  Amanda Linkous; Ling Geng; Andrej Lyshchik; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

6.  The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

Authors:  S L Spinelli; J J O'Brien; S Bancos; G M Lehmann; D L Springer; N Blumberg; C W Francis; M B Taubman; R P Phipps
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

7.  12-hydroxyeicosatetraenoic acid is associated with variability in aspirin-induced platelet inhibition.

Authors:  Benjamin H Maskrey; Gordon F Rushworth; Matthew H Law; Andrew T Treweeke; Jun Wei; Stephen J Leslie; Ian L Megson; Phillip D Whitfield
Journal:  J Inflamm (Lond)       Date:  2014-10-23       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.